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Cost-Effectiveness Analyses*
Sanket S. Dhruva, MD,yz Harlan M. Krumholz, MD, SMyxO ver the past 4 years, transcatheter aorticvalve replacement (TAVR) has transformedthe cardiac care of patients in the United
States with severe aortic stenosis (SAS). In September
2011, a balloon-expandable prosthesis (Sapien,
Edwards Lifesciences, Irvine, California) received
U.S. Food and Drug Administration (FDA) approval
for the treatment of inoperable patients on the basis
of a randomized trial showing improved 1-year mortal-
ity (50.7% vs. 30.7%) (1). This indication was extended
in September 2012 to high-risk patients after another
randomized trial showed similar 1-yearmortality in pa-
tients receiving TAVR and surgical aortic valve re-
placement (SAVR)—24.2% and 26.8%, respectively (2).
This device has been enhanced, leading to a most
recent FDA approval in June 2015 of the third-
generation balloon-expandable valve (3). In January
2014, the FDA also approved a self-expanding pros-
thesis (CoreValve, Medtronic, Dublin, Ireland) for
TAVR on the basis of nonrandomized data in patients
who were at prohibitive surgical risk (4).*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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MBBS, served as Guest Editor for this paper.The mortality and quality-of-life beneﬁts of TAVR
have led it to become a widely adopted therapy for
patients with SAS who are at prohibitive and high
surgical risk. Within the ﬁrst 19 months post-approval,
nearly 8,000 patients underwent TAVR (5). Estimates
project >100,000 TAVR candidates in North America
with >9,000 annual incident possible procedures (6).
However, TAVR is an expensive technology, and
treating all eligible North American patients with
TAVR would cost >$7 billion (7). Given these poten-
tially large expenses, cost-effectiveness analyses
are important to put the procedure in perspective
compared with alternative strategies. On the basis of
randomized data, TAVR in high surgical-risk patients
with the balloon-expandable valve was found to be
cost-effective only via the iliofemoral, but not the
transapical, route (8). In the overall population, the
incremental cost-effectiveness ratio (ICER) was
$76,877 per quality-adjusted life year (QALY) gained
(8). There are no cost-effectiveness analyses of the
self-expanding prosthesis, but its studies have
enrolled a slightly different patient population.SEE PAGE 29In this issue of the Journal, Reynolds et al. (9) pre-
sent a rigorous economic analysis using data from the
U.S. CoreValve High Risk Study, which randomized
795 patients (mean age 83 years, 53% male) with SAS
and New York Heart Association functional class II or
greater heart failure symptoms at increased surgical
risk to TAVR or SAVR (10). TAVR patients had lower
2-year mortality (11). Although both TAVR and SAVR
improved disease-speciﬁc and generic health status at
1 month, only patients receiving iliofemoral TAVR
had a signiﬁcant health status beneﬁt over SAVR
(12). This relative improvement was not sustained at
6 or 12 months. A relative beneﬁt isolated to iliofe-
moral patients is consistent with ﬁndings from high-
risk patients treated with the balloon-expandable
valve (13). This may be due to delayed recovery
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40because of a ministernotomy or minithoracotomy
used for direct aortic entry.
The investigators found that the higher technology
cost of the TAVR system ($32,000 commercially)
accounted for the largest proportion of TAVR ex-
penses. Shorter ICU and hospital lengths of stay offset
much of that charge, so overall in-hospital TAVR costs
were $11,260 more per patient over SAVR. At 12
months, TAVR cost $9,207 more than SAVR.
In the CoreValve High Risk study, data are likely
only generalizable to the study cohort: SAS patients
with New York Heart Association functional class II or
greater heart failure symptoms at increased surgical
risk (10). Of 995 screened patients, just 757 (76%) un-
derwent attempted TAVR or SAVR. This randomized
data must be supplemented by studies to ensure that
trial efﬁcacy is translated into real-world effective-
ness—and safety (14). Furthermore, early results in the
use of this technology may not be applicable to pa-
tients receiving TAVR later, because of improvements
gained through experience and device iterations.
Conclusions from cost-effectiveness analyses
depend onmodeling and discount rates, and Reynolds
et al. (9) integrated the self-expanding prosthesis’
survival and quality-of-life data based on U.S. health
care system conditions. They found an ICER of $55,090
for TAVR versus SAVR per QALY. Sensitivity analyses
suggested that reducing TAVR in-hospital costs by
about $1,650 would bring the ICER to <$50,000.
So, is this a good value? What level of cost-
effectiveness is reasonable? Should we quibble about
the $1,650 to meet this $50,000 threshold? Although
the $50,000 bar has unclear origins, it is frequently—
likely incorrectly—attributed to the U.S. Congress’
mandate that dialysis be paid for by taxpayer-funded
Medicare (15,16). Only in the past 2 decades has this
threshold even been widely used, possibly because it
is a convenient number (15,17). Cost-effectiveness
depends more on the costs that a health care system
is willing to bear. The World Health Organization
suggests a benchmark of 3 the gross domestic prod-
uct per capita as an upper threshold, which would be
about $150,000 per QALY in the United States—
signiﬁcantly higher than the $50,000 bar (18). No
matter the threshold, we have no precedent for
denying payment of therapies that show beneﬁt—even
for supremely expensive treatments. Indeed, Medi-
care is prohibited from considering cost in nearly all of
its coverage determinations (15).
More importantly, why do we care about cost-
effectiveness thresholds? We do not ration explicitly
such that a highly effective therapy is withheld from
people whose lives could be saved. Moreover, we pay
for many treatments with uncertain beneﬁts: 22% ofimplantable cardioverter-deﬁbrillator implantations
are not evidence-based, and 13% of nonacute percu-
taneous coronary interventions are classiﬁed as
inappropriate and 33% are classiﬁed as uncertain
(19,20). Also, the >$100 million that was spent
monthly on ezetimibe before any outcomes trials
provided evidence of its clinical beneﬁt indicates that
our health care system can sometimes pour resources
into uncertain therapies (21). Even with new treat-
ments lacking outcomes data, we similarly seem im-
mune to cost considerations: if only 5% of U.S. adults
with elevated low-density lipoprotein cholesterol
took the new PCSK9 inhibitors, annual insurance
premiums would increase by $124 for each person in
the pool (22). In these cases, the cost-effectiveness
ratio cannot be calculated with any conﬁdence
because of the uncertainty about effectiveness.
Perhaps these calculations are best used for
determining value and negotiating prices. Although
there is little precedent for using these calculations
for cost, many have called for payment based on
value. To do so, we must foremost rely on rigorous
clinical data to ensure that beneﬁts outweigh risks
and supplement them with observational data to
provide bounds to the estimates.
If cost-effectiveness analyses are to be useful, then
they must be timely and relevant to current clinical
practice. Ideally, cost-effectiveness analyses would
be available as close as possible to FDA approval. The
cost-effectiveness analysis of the self-expandable
valve was presented at the Transcatheter Cardiovas-
cular Therapeutics conference (held in Washington,
DC from September 13-17, 2014) about 8 months after
FDA approval, and is now being published in the
Journal. But there have already been important
developments: The device was approved for valve-
in-valve procedures in March 2015 and a new, recap-
turable self-expandable system was approved in June
2015 with a smaller sheath size that will likely allow
for more iliofemoral TAVR. Thus, this technology has
been evolving rapidly, and ideally, cost-effectiveness
analyses would be updated simultaneously and
also allow for comparison between the balloon-
expandable and self-expanding TAVR systems.
In addition to technological advances, treatment
paradigms for SAS are evolving from dependence on
classic aortic stenosis symptoms. Recent guidelines
give a Class IIa recommendation to AVR for patients
with very severe aortic stenosis but no symptoms (23).
A recent registry study published in the Journal sug-
gests that even patients with SAS who are asymptom-
atic may beneﬁt from AVR (24). And, although TAVR
has FDA approval only in high- and prohibitive-risk
patients, it is increasingly performed in Europe for
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41intermediate-risk patients while multiple trials in this
patient population are ongoing (7). Additionally, SAVR
outcomes have improved substantially over the past
decade (25). All of these factors related to aortic valve
disease, TAVR, and SAVRmust be considered in future
cost-effectiveness analyses.
At this time, the study by Reynolds et al. (9) makes
an important contribution as the ﬁrst cost-
effectiveness analysis of the self-expanding pros-
thesis. We are already paying for this technology
given the mortality and quality-of-life beneﬁts of
TAVR, and although we do not need to ﬁxate on
achieving the $50,000/QALY, we must monitor cost-effectiveness over time as science moves forward.
These analyses are likely to become increasingly
important as cost-consciousness takes a greater hold
in health care, and as a society, we will achieve
greater beneﬁt if we can curb misuse and direct our
resources toward beneﬁcial interventions. In
deciding what not to do based on cost, we should
start where effectiveness is unproven.
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